PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1901 Views
-
Last post by NHE
-
- 0 Replies
- 7718 Views
-
Last post by NHE
-
- 0 Replies
- 1682 Views
-
Last post by Firidion
-
- 0 Replies
- 869 Views
-
Last post by NHE
-
- 1 Replies
- 1229 Views
-
Last post by vesta
-
- 0 Replies
- 1843 Views
-
Last post by frodo
-
- 0 Replies
- 1800 Views
-
Last post by NHE
-
- 0 Replies
- 1331 Views
-
Last post by NHE
-
- 4 Replies
- 2245 Views
-
Last post by JohnC777